A prospective, observational non interventional cohort study.
King Abdul Aziz Medical City, Pediatric Cardiac ICU (PCICU), Riyadh.
Between April 2011 and May 2013, 257 patients admitted to our PCICU were recruited in the study.
Arterial and central venous blood samples were collected as needed per patients’ conditions. Patients’ clinical and laboratory data were collected simultaneously.
A total of 421 data sets with arterial, upper (SVC) and lower (FV) body central venous PCO2 were collected spontaneously from 257 patients age 17.0 ± 25.8 months, weight 7.45 ± 5.53 kg. UBPCO2G was higher than lower (art-FV) body PCO2 (LBPCO2G) gap 7.80 ± 3.28 vs. 5.95 ± 3.65 mmHg (p = 0.001. In 75% of our data sets UBPCO2G was 猢?.65 and LBPCO2 gap was 猢?.8 mmHg. Patients with UBPCO2G 猢?.65 vs. <9.65 mmHg had higher lactic acid (LA) 2.0 ± 1.4 vs. 1.6 ± 1.3 mmol/L (p = 0.014), BUN 6.1 ± 5.2 vs. 4.8 ± 2.1 mmol/L (p = 0.013), creatinine 48 ± 17 vs. 43 ± 13 渭mol/L (p = 0.004), glucose 8.7 ± 4.1 vs. 7.1 ± 3.7 mmol/L (p = 0.001) and PRISM score 9 ± 6 vs. 7 ± 6 (p = 0.038) and lower urine output 5.2 ± 2.8 vs. 6.1 ± 4.3 ml/kg/3 h. However patients with UBPCO2G 猢? vs. <6 mmHg were different in LA only 1.8 ± 1.5 vs. 1.5 ± 1.0 mmol/L, respectively (p = 0.018).
Upper is higher than lower body PCO2gap. UBPCO2G 猢?.65 was associated with higher LA, BUN, creatinine, serum glucose and PRISM and lower urine output. Patients with UBPCO2G 猢?.65 were sicker. UBPCO2G can be used as a biomarker in monitoring children with cardiac disease.